Format

Send to

Choose Destination
Obstet Gynecol Clin North Am. 2007 Dec;34(4):761-81, ix.

Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention.

Author information

1
Obstetrics and Gynecology, Public Health and Mexican-American Studies, National Center of Excellence in Women's Health, The University of Arizona, University Medical Center, 1501 North Campbell Avenue, Tucson, AZ 85724, USA. fcisco@u.arizona.edu

Abstract

Nearly all cervical cancers require human papillomavirus infection (HPV) for subsequent carcinogenesis. The identification of this obligate viral etiology, in addition to a vast knowledge about the HPV viral life cycle and resultant host response, has led to a vaccine approach to cervical cancer prevention. The use of prophylactic cancer vaccine as primary prevention holds the most promise for long-term cancer prevention but raises some important and as yet unanswered questions that are addressed in this article.

PMID:
18061868
DOI:
10.1016/j.ogc.2007.09.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center